Exercise Intolerance in Heart Failure

Description

The investigators are studying whether metabolic abnormalities in cardiac and skeletal muscle in patients with heart failure with preserved ejection fraction (HFpEF) are associated with debilitating exercise intolerance.

Conditions

Heart Failure With Normal Ejection Fraction

Talk to us

Study Overview

On this page

Study Details

Study overview

The investigators are studying whether metabolic abnormalities in cardiac and skeletal muscle in patients with heart failure with preserved ejection fraction (HFpEF) are associated with debilitating exercise intolerance.

Exercise Intolerance in Heart Failure: the Role of Altered Cardiac and Skeletal Muscle Energetics

Exercise Intolerance in Heart Failure

Condition
Heart Failure With Normal Ejection Fraction
Intervention / Treatment

-

Contacts and Locations

Baltimore

Johns Hopkins Hospital, Baltimore, Maryland, United States, 21287

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients of either gender who are greater than 21 years of age (no upper age limit),
  • * Permission of patient's clinical attending physician,
  • * Previous clinical diagnosis of HF with current New York Heart Association (NYHA) Class II-III symptoms for at least 1 month,
  • * Left ventricular ejection fraction (EF) \>50% by echocardiography, MRI, CT or x-ray or nuclear ventriculography within prior 12 months,
  • * Stable medical therapy for at least 30 days (no addition or removal or major (\>100%) dose change of Renin-Angiotensin-Aldosterone System (RAAS) antagonists, beta-blockers, or calcium channel blockers for hypertension).
  • * Unable to understand the risks, benefits, and alternatives of participation and give meaningful consent,
  • * Contraindications to MRI such as implanted metallic objects (pre-existing cardiac pacemakers, cerebral clips) or indwelling metallic projectiles,
  • * Significant valvular abnormalities,
  • * Pregnant women (women of childbearing potential will undergo blood or urine pregnancy testing),
  • * History of clinical CAD or significant epicardial coronary disease (\>50% stenosis) in major coronary artery by x-ray or CT angiography unless (a) the patient underwent prior successful revascularization with percutaneous coronary angioplasty within the prior three years and (b) there are no residual lesions of \>50% on the most recent coronary angiographic study.
  • * History of infiltrative cardiomyopathy or constrictive pericarditis,
  • * Cor pulmonale,
  • * Significant pulmonary disease,
  • * Estimated glomerular filtration rate (eGFR) \<20ml/min,
  • * Any condition other than HF which could limit the ability to perform a 6MW or cardiopulmonary exercise test (CPET) test (e.g., critical peripheral vascular disease, significant orthopedic or neurological conditions),
  • * Any diseases other than HF which are likely to significantly alter the patient's global perception of status or quality of life over a period of 6 months.
  • * Significant peripheral vascular disease

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Johns Hopkins University,

Robert G Weiss, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

2025-03